BOT Share Price Performance
AU$0
-0.42 (-100.00%)
Price AU$0
Fair ValueAU$0.83
Share Pricen/a
Botanix Pharmaceuticals Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 89 Fair Values set on narratives written by author
BOT Community Narratives
AN
Fair Value AU$0.83 93.7% undervalued intrinsic discount
Long-Term Hyperhidrosis Demand And Fulfillment Platform Will Support This Bullish Thesis
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Long-Term Hyperhidrosis Demand And Fulfillment Platform Will Support This Bullish Thesis
Catalysts About Botanix Pharmaceuticals Botanix Pharmaceuticals is a dermatology company focused on Sofdra, a prescription treatment for primary axillary hyperhidrosis. What are the underlying business or industry changes driving this perspective?Read more
63
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AU$0.83
93.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
0.52%
Future PE
1.81kx
Price in 2029
AU$1.01
Trending Discussion
Recently Updated Narratives
AN
Long-Term Hyperhidrosis Demand And Fulfillment Platform Will Support This Bullish Thesis
Fair Value: AU$0.83 93.7% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Botanix Pharmaceuticals Limited Key Details
About BOT
- Founded
- 1984
- Employees
- n/a
- CEO
- WebsiteView website
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis. The company was incorporated in 1984 and is based in West Perth, Australia.
